Mark Nelson

Summary

Affiliation: Chelsea and Westminster Hospital
Country: UK

Publications

  1. ncbi The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years
    Mark R Nelson
    Department of HIV and Genitourinary Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London, UK
    AIDS 21:1273-81. 2007
  2. ncbi Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials
    Mark Nelson
    Chelsea and Westminster Hospital, St Stephen s Centre, London, UK
    J Antimicrob Chemother 67:2020-8. 2012
  3. ncbi Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort
    Carlo Torti
    Istituto di Malattie Infettive e Tropicali, Universita degli Studi di Brescia, p le Spedali Civili 1, Brescia, Italy
    BMC Infect Dis 5:58. 2005
  4. ncbi The role of NNRTIs in antiretroviral combination therapy: an introduction
    M Nelson
    Chelsea and Westminster Hospital, London, UK
    Int J STD AIDS 12:1-2. 2001
  5. ncbi Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials
    Mark Nelson
    Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 40:404-12. 2005
  6. ncbi Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data
    Mark Nelson
    Chelsea and Westminster Hospital, London, UK
    J Antimicrob Chemother 65:1505-9. 2010
  7. ncbi Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc plus optimized background therapy in the MOTIVATE 1 and 2 trials
    Mark Nelson
    Chelsea and Westminster Hospital, London, UK
    HIV Clin Trials 11:145-55. 2010
  8. ncbi Management of advanced HIV disease in patients with tuberculosis or hepatitis co-infection
    M Nelson
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    Int J Clin Pract 60:976-83. 2006
  9. ncbi A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population
    Mark Nelson
    St Stephens Centre, Chelsea and Westminster Hospital, London, UK
    AIDS 25:335-40. 2011
  10. ncbi Emtricitabine (FTC) for the treatment of HIV infection
    M Nelson
    Chelsea and Westminster Hospital, HIV Medicine, London, UK
    Int J Clin Pract 58:504-10. 2004

Detail Information

Publications106 found, 100 shown here

  1. ncbi The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years
    Mark R Nelson
    Department of HIV and Genitourinary Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London, UK
    AIDS 21:1273-81. 2007
    ..To characterize the safety profile of tenofovir disoproxil fumarate (DF) for the treatment of HIV infection in adults over the first 4 years of use...
  2. ncbi Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials
    Mark Nelson
    Chelsea and Westminster Hospital, St Stephen s Centre, London, UK
    J Antimicrob Chemother 67:2020-8. 2012
    ....
  3. ncbi Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort
    Carlo Torti
    Istituto di Malattie Infettive e Tropicali, Universita degli Studi di Brescia, p le Spedali Civili 1, Brescia, Italy
    BMC Infect Dis 5:58. 2005
    ....
  4. ncbi The role of NNRTIs in antiretroviral combination therapy: an introduction
    M Nelson
    Chelsea and Westminster Hospital, London, UK
    Int J STD AIDS 12:1-2. 2001
    ....
  5. ncbi Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials
    Mark Nelson
    Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 40:404-12. 2005
    ....
  6. ncbi Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data
    Mark Nelson
    Chelsea and Westminster Hospital, London, UK
    J Antimicrob Chemother 65:1505-9. 2010
    ..To examine how treatment adherence differences in ARTEMIS (96 week analysis) affected clinical outcome, and to assess factors impacting adherence...
  7. ncbi Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc plus optimized background therapy in the MOTIVATE 1 and 2 trials
    Mark Nelson
    Chelsea and Westminster Hospital, London, UK
    HIV Clin Trials 11:145-55. 2010
    ..This post hoc analysis compared outcomes between patients with and without HIV-1 resistance to epsilon3 classes of antiretrovirals at screening (triple-class-resistant [TCR] versus not-TCR [nTCR])...
  8. ncbi Management of advanced HIV disease in patients with tuberculosis or hepatitis co-infection
    M Nelson
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    Int J Clin Pract 60:976-83. 2006
    ..The aim is to offer practical advice on therapeutic options for treatment-naïve patients who present with advanced HIV disease on the basis of available clinical evidence...
  9. ncbi A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population
    Mark Nelson
    St Stephens Centre, Chelsea and Westminster Hospital, London, UK
    AIDS 25:335-40. 2011
    ..Although efavirenz is a universally recommended treatment for naive HIV-infected individuals, neuropsychiatric adverse events are common...
  10. ncbi Emtricitabine (FTC) for the treatment of HIV infection
    M Nelson
    Chelsea and Westminster Hospital, HIV Medicine, London, UK
    Int J Clin Pract 58:504-10. 2004
    ....
  11. ncbi Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients
    Marta Boffito
    PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    J Acquir Immune Defic Syndr 37:1376-84. 2004
    ..This study evaluated the steady-state pharmacokinetics of saquinavir 1000 mg twice daily (bid) and fosamprenavir 700 mg bid administered with 2 different doses of ritonavir (100 and 200 mg bid) in HIV-1-infected subjects...
  12. ncbi Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients
    Lauro J Waters
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    Antivir Ther 12:825-30. 2007
    ..This study investigated the steady-state plasma pharmacokinetics of abacavir when co-administered with atazanavir/ritonavir or lopinavir/ritonavir in HIV-infected individuals...
  13. ncbi Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects
    Marta Boffito
    PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    Br J Clin Pharmacol 59:38-42. 2005
    ..To investigate whether the administration of tenofovir diproxil fumarate 300 mg once daily alters the plasma pharmacokinetics of the saquinavir hard gel/ritonavir combination in HIV-1 infected individuals...
  14. ncbi Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance
    Marta Boffito
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    AIDS 21:1449-55. 2007
    ..Cumulative antiretroviral exposure can result in multiclass HIV drug resistance. Experimental antiretroviral agents offer limited therapeutic benefit as resistance quickly develops after their introduction as a sole new agent...
  15. ncbi Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses
    Marta Boffito
    Chelsea and Westminster Hospital, London, United Kingdom
    AIDS Res Hum Retroviruses 22:749-56. 2006
    ..Atazanavir-related hyperbilirubinemia was dose dependent. However, higher saquinavir and atazanavir exposure may be required to suppress HIV-resistant strain replication...
  16. ncbi Studies on the allostimulatory function of dendritic cells from HCV-HIV-1 co-infected patients
    Justin Stebbing
    The Department of Immunology, Division of Investigative Science, Faculty of Medicine, Imperial College of Science, Technology and Medicine, The Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    Cell Res 14:251-6. 2004
    ..These findings are compatible with results of prior clinical studies that found no evidence that HCV co-infection altered HIV disease progression and has implications for immunotherapeutic approaches in co-infected individuals...
  17. ncbi An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy
    Graeme Moyle
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 11:73-8. 2006
    ..To examine the antiviral potency and tolerability profile of a single-class four drug (quadruple) nucleoside reverse transcriptase inhibitor (NRTI) regimen compared with a 2-class standard-of-care regimen...
  18. ncbi Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial
    Desmond Maitland
    Chelsea and Westminster Hospital, London, UK
    AIDS 19:1183-8. 2005
    ....
  19. ncbi Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily
    Marta Boffito
    PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    J Antimicrob Chemother 55:542-5. 2005
    ..This study examined the pharmacokinetics of twice-daily saquinavir-hg (1000 mg) in the presence of ritonavir 100 mg, dosed twice-daily and once-daily on one single occasion...
  20. ncbi Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol
    Victoria Latham
    The St Stephen's Centre, The Chelsea and Westminster Hospital, London, UK
    J Antimicrob Chemother 56:186-9. 2005
    ..CONCLUSIONS: In compliant heavily pre-treated individuals with less than 2 TAMs, salvage therapy with trizivir and tenofovir is associated with suppression of viraemia and an improved lipid profile...
  21. ncbi Prognostic significance of immune subset measurement in individuals with AIDS-associated Kaposi's sarcoma
    Justin Stebbing
    Imperial College of Science, Medicine, and Technology, Department of Oncology, The Chelsea and Westminster Hospital, London, United Kingdom
    J Clin Oncol 25:2230-5. 2007
    ..Because immune subset measurement is often performed in HIV-positive individuals, we examined whether these were predictive of mortality independently of the prognostic index, or could predict time to progression of KS...
  22. ncbi Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients
    Jennifer Ford
    Department of Pharmacology and Therapeutics, University of Liverpool, 70 Pembroke Place, Liverpool L69 3GF, and PK Research Ltd, St Stephen's Centre, Chelsea and Westminster Hospital, London, UK
    J Antimicrob Chemother 58:1009-16. 2006
    ..Co-administration of atazanavir caused an increase in both the plasma and cellular exposure (AUC0-24) and C24 of saquinavir but not ritonavir...
  23. ncbi The risks and incidence of K65R and L74V mutations and subsequent virologic responses
    Laura Waters
    Department of HIV Medicine, Chelsea and Westminster Hospital and Imperial College School of Medicine, London, United Kingdom
    Clin Infect Dis 46:96-100. 2008
    ..If suboptimal HAART was used, patients with K65R experienced significantly higher rates of virologic suppression than did those with L74V (P = .01)...
  24. ncbi A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine
    Laura Waters
    Chelsea and Westminster Hospital, London, UK
    AIDS 25:65-71. 2011
    ..Most EFV-related central nervous system (CNS) toxicity resolves early though symptoms may persist; we studied switching to etravirine (ETR) in these individuals...
  25. ncbi Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events
    Justin Stebbing
    Department of HIV Medicine, Chelsea and Westminster Hospital, London, United Kingdom
    Clin Infect Dis 41:906-11. 2005
    ..In conclusion, there was an increased number of adverse events in coinfected individuals, compared with individuals infected with HIV-1 alone...
  26. ncbi Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir
    Neesha Rockwood
    Department of HIV Medicine, Chelsea and Westminster Hospital, London, UK
    AIDS 25:1671-3. 2011
    ..When choosing a boosted protease inhibitor, ATZ/r renal stones should be considered as a potential comorbidity...
  27. ncbi New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists
    Amelia Hughes
    Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    J Infect 57:1-10. 2008
    ..This article is a review of currently available antiretroviral agents including the new classes and second generation drugs, resistance pathways and treatment options for salvage therapy...
  28. ncbi The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma
    Justin Stebbing
    Department of Immunology, Division of Investigative Science, Faculty of Medicine, Imperial College of Science, Technology and Medicine, The Chelsea and Westminster Hospital, London, United Kingdom
    Int J Cancer 108:631-3. 2004
    ..This is consistent with data suggesting that regression of KS is mediated by an overall improvement in immune function and not by the effects of specific antiretrovirals...
  29. ncbi Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals
    Andrew Scourfield
    Department of HIV Medicine, Chelsea and Westminster Hospital, Chelsea, UK
    AIDS 26:1399-401. 2012
    ..We aimed to describe the outcomes of individuals commencing Atripla (Gilead Sciences Inc, Foster City, California; Bristol-Myers Squibb Co, Princeton, New Jersey, USA) as a first-line regimen...
  30. ncbi Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?
    Alan Winston
    Department of Genitourinary and HIV Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    AIDS 18:572-4. 2004
    ..It was found that when changing from efavirenz to nevirapine individuals should commence on 200 mg twice a day, as this dose is associated with therapeutic plasma drug levels...
  31. ncbi HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome?
    Mark Bower
    Department of Oncology, Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 37:1563-5. 2004
    ..We wished to evaluate its effects on incidence and survival in HIV-associated anal cancer...
  32. ncbi A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy
    Justin Stebbing
    Department of Oncology, Chelsea and Westminster Hospital, London SW10 9NH, UK
    Lancet 367:1495-502. 2006
    ..We developed a simple model for predicting mortality on the basis of clinical characteristics present at the time of diagnosis of Kaposi's sarcoma...
  33. ncbi HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation
    Alan Steel
    Department of Immunology, Imperial College, Chelsea and Westminster Hospital, London
    Antivir Ther 12:971-5. 2007
    ..To determine if the expression of CD38 on CD8+ T-cells could be used as a marker of viral replication <50 copies/ml in peripheral blood...
  34. ncbi Virological failure and subsequent resistance profiles in individuals exposed to atazanavir
    Justin Stebbing
    Department of HIV Medicine, The Chelsea and Westminster Hospital, Imperial College School of Science, Technology and Medicine, London, UK
    AIDS 21:1826-8. 2007
    ..This is particularly important because of the increasing use of atazanavir monotherapy, and implies that treatment failure is caused by lack of potency...
  35. ncbi A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART)
    Justin Stebbing
    The St Stephen s Centre, The Chelsea and Westminster Hospital, London, UK
    J Antimicrob Chemother 53:501-5. 2004
    ....
  36. ncbi A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma
    Simon Portsmouth
    Department of Immunology, Chelsea and Westminster Hospital, London, UK
    AIDS 17:F17-22. 2003
    ..CONCLUSION: PI- and NNRTI-based HAART regimens are equally effective as protection against KS. This is the first study to demonstrate a decreased incidence of an AIDS-defining disease with NNRTI-based therapy...
  37. ncbi A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy
    Mark Bower
    The Chelsea and Westminster Hospital, London, United Kingdom
    Ann Intern Med 143:265-73. 2005
    ..The established International Prognostic Index for lymphomas has not included patients with systemic AIDS-related non-Hodgkin lymphoma...
  38. ncbi Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc
    Darius Armstrong-James
    Imperial College, St Stephens AIDS Trust, Chelsea and Westminster Hospital, London, UK
    Antiviral Res 86:224-6. 2010
    ..Further studies are required to assess the clinical efficacy of maraviroc in HIV-2 infection...
  39. ncbi Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era
    Douglas C Macdonald
    Chelsea and Westminster Hospital, London, United Kingdom
    World J Gastroenterol 14:1657-63. 2008
    ..Once HCC develops, there is growing evidence that HIV co-infection should not preclude conventional therapeutic strategies, including liver transplantation...
  40. ncbi Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study
    Rachael Jones
    Department of HIV and Genitourinary Medicine, The Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 37:1489-95. 2004
    ..We investigated the overall incidence and risk of renal dysfunction in individuals receiving tenofovir DF and compared this with other antiretrovirals...
  41. ncbi Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease
    Justin Stebbing
    Department of HIV Medicine, Imperial College, Chelsea and Westminster Hospital, London, United Kingdom
    Blood 118:271-5. 2011
    ..Rising levels predicted an attack (hazard ratio = 2.9; 95% confidence interval, 1.3-6.7), and maintenance therapy with rituximab should be considered in these individuals...
  42. ncbi Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma
    Mark Bower
    Department of Oncology, Imperial College School of Medicine, London, UK
    Blood 111:3986-90. 2008
    ..Chemotherapy and concomitant HAART for AIDS-related NHL does not cause prolonged suppression of lymphocyte subsets. These data should provide reassurance regarding the long-term consequences of chemotherapy in these individuals...
  43. ncbi The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals
    Naa Torshie Annan
    Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom
    J Acquir Immune Defic Syndr 51:140-6. 2009
    ....
  44. ncbi Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease
    Mark Bower
    Department of Oncology, HIV Medicine and Immunology, Imperial College School of Medicine, Chelsea and Westminster Hospital, London, United Kingdom
    Blood 113:4521-4. 2009
    ..Therapies that reduce the inflammatory cytokine response are likely to be successful in a range of diseases, including HIV-MCD, and in the future may be used to guide therapeutic strategies...
  45. ncbi Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase
    Alan Winston
    Department of GU and HIV Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    AIDS 18:949-51. 2004
  46. ncbi Nadir B cell counts are significantly correlated with the risk of Kaposi's sarcoma
    Justin Stebbing
    Department of Immunology, Division of Investigative Science, Faculty of Medicine, Imperial College of Science, Technology and Medicine, The Chelsea and Westminster Hospital, London, United Kingdom
    Int J Cancer 108:473-4. 2004
    ..015). These data highlight a potential role for B cells and therefore the humoral immune system in KS aetiopathogenesis...
  47. ncbi Hepatitis C infection is not associated with systemic HIV-associated non-Hodgkin's lymphoma: a cohort study
    Laura Waters
    Department of HIV Medicine, The Chelsea and Westminster Hospital, London, United Kingdom
    Int J Cancer 116:161-3. 2005
    ..1 of 10(4) patient years during HIV alone (p = 0.9). In this immunocompromised patient population, there was no association between HCV infection and an increased risk of lymphoma...
  48. ncbi Use of antidepressants and risk of cancer in individuals infected with HIV
    Justin Stebbing
    Imperial College, Imperial Healthcare NHS Trust, Charing Cross Hospital, Department of Medical Oncology, London, UK
    J Clin Oncol 26:2305-10. 2008
    ..We aimed to assess whether different classes of antidepressants were associated with changes in cancer incidence in a population of HIV-1 infected individuals, based on duration of exposure...
  49. ncbi Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 9:423-9. 2004
    ..To evaluate the steady-state pharmacokinetics and safety of two once-daily saquinavir/ritonavir (SQV/RTV) regimens, 1600/100 and 2000/100 mg, in HIV-positive patients...
  50. ncbi Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours
    Mark Danta
    UCL Institute of Hepatology, London, UK
    AIDS 21:983-91. 2007
    ..To characterize the mode of hepatitis C virus (HCV) transmission in a recent epidemic of acute HCV in HIV-infected individuals using linked molecular and clinical epidemiological studies...
  51. ncbi Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patients
    Guglielmo Rosignoli
    Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, London, UK
    AIDS 21:1379-81. 2007
    ..We found raised levels of PD-L1 in aviraemic chronically infected HIV-1-positive patients, which may contribute to incomplete immune reconstitution after treatment with HAART...
  52. ncbi Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease
    Melanie Hart
    Department of Immunology, Imperial College, Chelsea and Westminster Hospital, London, United Kingdom
    J Immunol 178:8212-20. 2007
    ....
  53. ncbi CCR5 antagonism impacts vaccination response and immune profile in HIV-1 infection
    Samantha J Westrop
    Department of Medicine, Imperial College London, London, UK
    Mol Med 18:1240-8. 2012
    ....
  54. ncbi Antibody-targeted MHC complex-directed expansion of HIV-1- and KSHV-specific CD8+ lymphocytes: a new approach to therapeutic vaccination
    Justin Stebbing
    Department of Immunology, Division of Investigative Science, Faculty of Medicine, Imperial College of Science, Technology, and Medicine, The Chelsea and Westminster Hospital, London, United Kingdom
    Blood 103:1791-5. 2004
    ..This approach, which offers an easy and effective protocol for the amplification of specific antiviral and antitumor CTLs, may offer significant advances for in vivo T-cell immunotherapeutic protocols...
  55. ncbi Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels
    Tom Newsom-Davis
    Departments of Oncology and HIV Medicine, Chelsea and Westminster Hospital, London SW10 9NH, UK
    Leuk Lymphoma 45:1939-41. 2004
    ..This highlights the close association between circulating cytokines such as IL-6 and virally-induced malignancy...
  56. ncbi Brief communication: rituximab in HIV-associated multicentric Castleman disease
    Mark Bower
    Department of Oncology, Imperial College, The Chelsea and Westminster Hospital, Barts and The London NHS Trust, and Queen Mary s University, London, United Kingdom
    Ann Intern Med 147:836-9. 2007
    ..Many therapeutic approaches in small series of patients have proved largely unsuccessful to date...
  57. ncbi FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease
    Rob Barker
    Department of Radiology, Imperial College School of Medicine, The Chelsea and Westminster Hospital, London, UK
    Eur J Nucl Med Mol Imaging 36:648-52. 2009
    ..To evaluate the role of FDG-PET/CT scanning in the management of HIV-associated multicentric Castleman's disease (MCD) a rare lymphoproliferative disorder associated with infection by human herpesvirus 8 (HHV8)...
  58. ncbi The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma
    Mark Bower
    Department of Oncology, Chelsea and Westminster Hospital, London, UK
    AIDS 23:1701-6. 2009
    ..A prospective cohort study was performed to evaluate the clinical outcomes of patients with histologically confirmed AIDS-related Kaposi's sarcoma diagnosed since the introduction of HAART...
  59. ncbi Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART)
    Loveleen Bansi
    HIV Epidemiology nad Biostatistics Group, Research Department of Infection and Population Health, Division of Population Health, Hampstead Campus, University College Medical School, University College London, Rowland Street, NW3 2PF, London, United Kingdom
    J Acquir Immune Defic Syndr 53:633-9. 2010
    ..The study aim was to determine how resistance testing influences outcome of first-line highly active antiretroviral therapy (HAART) in routine practice in the United Kingdom...
  60. ncbi The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1-infected "true" long-term nonprogressors
    Justin Stebbing
    Department of Immunology, Division of Investigative Science, Faculty of Medicine, Imperial College of Science, Technology and Medicine, The Chelsea and Westminster Hospital, London, United Kingdom
    Blood 101:4000-4. 2003
    ..The ability of CD91 to internalize alpha-defensins and to cross-present exogenous antigen to cytotoxic T lymphocytes through major histocompatibility complex (MHC) class 1 may maintain CD8(+) responses in these patients...
  61. ncbi Are long-term non-progressors very slow progressors? Insights from the Chelsea and Westminster HIV cohort, 1988-2010
    Sundhiya Mandalia
    Department of Medicine, Imperial College London, Chelsea and Westminster Hospital, London, United Kingdom
    PLoS ONE 7:e29844. 2012
    ..Few LTNP and HIC identified in this and other studies, endorse the need for universal definitions to facilitate comparison...
  62. ncbi Drug combinations for HIV: what's new?
    Andrew Scourfield
    1st Floor, St Stephen s Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
    Expert Rev Anti Infect Ther 9:1001-11. 2011
    ..This article will focus on the evidence for current therapies and strategies in ART-naive individuals and the potential for use of novel agents in the future...
  63. ncbi Evaluation of filter paper transfer of whole-blood and plasma samples for quantifying HIV RNA in subjects on antiretroviral therapy in Uganda
    Laura Waters
    St Stephens AIDS Trust, Chelsea and Westminster Hospital, London, UK
    J Acquir Immune Defic Syndr 46:590-3. 2007
    ..We investigated filter paper transfer (FPT) of whole blood and plasma as an alternative to standard plasma-based assays for virologic monitoring in Uganda...
  64. ncbi Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience
    Laura J Waters
    Department of GU HIV Medicine, St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    AIDS 21:2533-4. 2007
    ..We describe our experience of prospective HLA-B5701 testing and the impact on rates of abacavir hypersensitivity...
  65. ncbi Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy
    Mark Nelson
    Imperial College, Department of HIV Medicine, Chelsea and Westminster Hospital, London, UK
    AIDS 22:1374-6. 2008
    ..We recommend that both the above nucleosides be added to the list of antiretroviral drugs that can induce Fanconi syndrome and that patients on stavudine and lamivudine be monitored carefully for early signs of Fanconi syndrome...
  66. ncbi The evolution of coreceptor tropism in HIV-infected patients interrupting suppressive antiretroviral therapy
    Laura J Waters
    Department of Genitourinary HIV Medicine, Chelsea and Westminster Hospital Foundation Trust, London, United Kingdom
    Clin Infect Dis 52:671-3. 2011
    ..Tropism switching after suppressive ART was uncommon in this cohort. Pretreatment human immunodeficiency virus (HIV) RNA tropism testing may help guide the switch to CCR5 antagonists in patients with undetectable HIV RNA...
  67. ncbi The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma
    Ben Esdaile
    Department of Oncology, Chelsea and Westminster Hospital, London, UK
    AIDS 16:2344-7. 2002
    ..We showed in 50 patients that liposomal anthracyclines used with HAART did not lead to a significant loss of CD4 or CD8 cells or an increase in HIV-1 viral load during or up to 12 months after chemotherapy...
  68. ncbi HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?
    Martin Vogel
    Department of HIV Medicine, Chelsea and Westminster Hospital, London, UK
    Eur J Med Res 14:36-42. 2009
    ..In the following review we want to focus on the new class of HIV integrase inhibitors and discuss present data with regard to special issues of HIV and HCV co-infection...
  69. ncbi Cryptococcal disease and HIV infection
    Laura Waters
    Chelsea and Westminster Hospital, 369 Fulham Road, SW11 5AJ, UK
    Expert Opin Pharmacother 6:2633-44. 2005
    ..This article reviews the epidemiology, clinical features and management of cryptococcal disease in HIV-infected patients, particularly focusing on the history of, current guidelines for and future developments in antifungal therapy...
  70. ncbi A meta-analysis of transient elastography for the detection of hepatic fibrosis
    Justin Stebbing
    Department of HIV Medicine, Chelsea and Westminster Hospital, St Stephen s Centre, Imperial College School of Medicine, London, UK
    J Clin Gastroenterol 44:214-9. 2010
    ..We performed a meta-analysis to further assess its use in comparison with liver biopsy...
  71. ncbi Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals
    Colette J Smith
    Royal Free Centre for HIV Medicine and Department of Primary Care and Population Sciences, Royal Free and University College Medical School, Royal Free Campus, London, United Kingdom
    J Acquir Immune Defic Syndr 37:1155-9. 2004
    ..We suggest that this group of patients should be particularly closely monitored...
  72. ncbi Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma
    Tom Powles
    Department of Oncology, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    AIDS 16:531-6. 2002
    ..The CD4 T-cell count falls by 50% during chemotherapy and this will help to identify patients who require opportunistic infection prophylaxis during chemotherapy...
  73. ncbi Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study
    Gail V Matthews
    Department of HIV Medicine, Chelsea Hospital, London, UK
    AIDS 16:53-61. 2002
    ..Clinical trial data is required to confirm these findings...
  74. ncbi A case of immune reconstitution rheumatoid arthritis
    Charlotte Bell
    Department of HIV, St Stevens Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    Int J STD AIDS 13:580-1. 2002
  75. ncbi The use of caspofungin in HIV-infected individuals
    Laura Waters
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    Expert Opin Investig Drugs 16:899-908. 2007
    ..Finally, evidence for the use of caspofungin for the treatment of Pneumocystis jiroveci pneumonia, an unlicensed indication, including a case series from our own unit is explored...
  76. ncbi Acute hepatitis C in HIV-positive individuals
    Emma Low
    Department of Sexual Health and HIV, Chelsea and Westminster Hospital, London, UK
    AIDS Rev 10:245-53. 2008
    ..In the meantime, units faced with HIV/acute hepatitis C coinfection should follow recommendations from the HCV-HIV International Panel...
  77. ncbi Treatment of acute hepatitis C virus infection in HIV-infected individuals
    Emma Low
    Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    J HIV Ther 12:7-10. 2007
  78. ncbi The role of receptors in the HIV-1 entry process
    Rachael Jones
    Department of HIV and GU Medicine, The Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, United Kingdom
    Eur J Med Res 12:391-6. 2007
    ..This article discusses how the entry inhibitors may meet many of these challenges and preserve the reduced morbidity and mortality we have come to expect from HAART use...
  79. ncbi Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    AIDS 18:1291-7. 2004
    ..To determine the pharmacokinetics of saquinavir hard-gel capsules/ritonavir/atazanavir co-administered once daily at 1600/100/300 mg in HIV-infected individuals...
  80. ncbi Clearance of hepatitis C virus RNA from serum in HIV/hepatitis C virus coinfection indicates eradication from peripheral blood mononuclear cells
    Emma E Page
    Chelsea and Westminster NHS Foundation Trust, London, UK
    AIDS 24:1267-71. 2010
    ....
  81. ncbi Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin
    Yvonne C Gilleece
    St. Stephen's Centre, Chelsea and Westminster Hospital, London, UK
    J Acquir Immune Defic Syndr 40:41-6. 2005
    ..Because a high percentage of individuals seroconvert spontaneously, treatment should be delayed until after 12 weeks...
  82. ncbi Tetanus vaccination with IL-2 during highly active antiretroviral therapy induces sustained and pronounced specific CD4 T-cell responses
    Gareth A D Hardy
    Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, London, UK
    AIDS 18:2199-202. 2004
    ..We report the effects of IL-2 given with tetanus vaccination in two patients in a larger immunotherapy study. In one case IL-2 induced sustained responses, which may have been caused by the timing of IL-2 with vaccination...
  83. ncbi Interleukin-2-associated viral breakthroughs induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active antiretroviral therapy
    Ann K Sullivan
    St Stephen's Centre, Chelsea and Westminster Hospital, London, UK
    AIDS 17:628-9. 2003
    ..This immunotherapeutic approach, utilizing autologous virus as autovaccination, may be a viable, safer alternative to structured treatment interruption and potentially more efficacious than therapeutic vaccines...
  84. ncbi New therapeutic options for hepatitis C
    Laura Waters
    Department of GU and HIV Medicine, Chelsea and Westminster Hospital, London, UK
    Curr Opin Infect Dis 19:615-22. 2006
    ..Much progress has been made in terms of maximizing success with currently licensed agents and lessons learned from the field of HIV can guide the careful use of new agents to minimize resistance in the future...
  85. ncbi Building the best regimen for highly treatment-experienced patients
    Mark R Nelson
    St Stephen's Centre, Chelsea and Westminster Hospital, London, UK
    J HIV Ther 7:102-5. 2002
    ....
  86. ncbi New drugs
    Laura Waters
    Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    J HIV Ther 10:16-8. 2005
  87. ncbi Hepatocellular cancer in HIV-infected individuals: tomorrow's problem?
    Thomas Powles
    St Bartholomew s Hospital, Department of Medical Oncology, London, UK
    Expert Rev Anticancer Ther 6:1553-8. 2006
    ..It also attempts to predict future areas of importance in the management of these patients in the era of highly active antiretroviral therapy...
  88. ncbi HIV entry: new insights and implications for patient management
    Amelia Hughes
    St Stephens Centre, Chelsea and Westminster NHS Foundation Trust, London, UK
    Curr Opin Infect Dis 22:35-42. 2009
    ..This review article reports the recent published data regarding licensed and investigational HIV entry inhibitors including CCR5 and CXCR4 antagonists, fusion inhibitors and attachment inhibitors...
  89. ncbi Guillain--Barre syndrome following immune reconstitution after antiretroviral therapy for primary HIV infection
    E C Y Teo
    Imperial College School of Medicine, London, UK
    J HIV Ther 12:62-3. 2007
  90. ncbi HIV and hepatitis B: a review
    Claire Thomas
    Chelsea and Westminster Hospital, 369 Fulham Road London, United Kingdom
    AIDS Patient Care STDS 17:623-33. 2003
  91. ncbi Case report. Severe cutaneous ulceration secondary to cytomegalovirus inclusion disease during successful immune reconstitution with HAART
    Nadeem A Qazi
    Kobler Clinic, St. Stephen's Centre, Chelsea and Westminster Hospital, London, UK
    AIDS Read 12:452-4, 456-7. 2002
    ....
  92. ncbi A case of march fracture in a patient with osteoporosis on long-term HAART
    Sophie F Forsyth
    Kobler Centre, St Stephen's Centre, Chelsea and Westminster Hospital, London, UK
    Int J STD AIDS 13:645-6. 2002
  93. ncbi Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis
    Christos Michailidis
    Chelsea and Westminster Hospital NHS Trust, London, UK
    Antivir Ther 10:417-22. 2005
    ..046). CONCLUSIONS: Patients who develop IRIS are more likely to present with disseminated TB, have a CD4 count < 100 cells/mm3 and have a prompt rise in CD4 count in the initial 3 months of HAART...
  94. ncbi Transient nature of long-term nonprogression and broad virus-specific proliferative T-cell responses with sustained thymic output in HIV-1 controllers
    Samantha J Westrop
    Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, London, United Kingdom
    PLoS ONE 4:e5474. 2009
    ..In the absence of universal definition, immune function in such HIV controllers remains an indication of non-progression...
  95. ncbi Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection
    Gregory J Dore
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    AIDS 21:1555-9. 2007
    ..To identify baseline characteristics predictive of a sustained virological response (SVR) in patients with HIV-hepatitis C virus (HCV) co-infection treated with interferon-based therapy...
  96. ncbi Gynaecomastia without lipodystrophy in HIV-1-seropositive patients on efavirenz: an alternative hypothesis
    Nadeem A Qazi
    AIDS 16:506-7. 2002
  97. ncbi Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors?
    John F Morlese
    AIDS 16:1840-1. 2002
  98. ncbi Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  99. ncbi Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  100. ncbi The efficacy of lopinavir in individuals experiencing protease inhibitor failure
    Yvonne C Gilleece
    J Acquir Immune Defic Syndr 32:238-40. 2003
  101. ncbi True gynaecomastia, another manifestation of immune reconstitution disease?
    Nadeem A Qazi
    Int J STD AIDS 13:59-65. 2002